Motion perception with 5-HT2 receptor-blocking medications

Chentel Christman, Stephen Setterberg, Mark Nawrot

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

It has been suggested that medications blocking 5- HT2 receptors may produce a selective motion perception deficit called akinetopsia. Horton and Trobe (1999) reported two cases of transient akinetopsia resulting from high doses of serzone (nefazadone). However, it is difficult to distinguish akinetopsia from more common visual side effects including palinopsia, a prolonged image of an object after it has moved or the observer looks away, and polyopia, multiple images of a moving object, based solely on patient report. Moreover, it is known that another similar 5- HT2 blocker, trazodone, lowers flicker fusion frequency (Riedel et al, 1999) although its effect on motion perception has not been investigated. In the current study, flicker fusion frequency (FFF) and motion perception were assessed in outpatients taking prescribed therapeutic doses of serzone and trazodone. FFF was assessed with LED's using method of limits with ascending and descending trials. Motion perception was assessed with the Ternus display and with a random-dot cinematogram display. The Ternus display used a 2AFC (element/group movement) task as inter-frame-interval varied between 0 and 60 msec. The random-dot cinematogram task used a 4AFC (up/down/left/right) task as the proportion of motion signal varied between 6% and 34%. Similar to Riedel et al (1999), the medicated outpatient group had significantly lower FFF than the normal control group. However, on the motion perception tasks, performance within the outpatient group was highly variable, but overall, the outpatient and normal groups were not significantly different. It appears that typical therapeutic doses of these 5- HT2 blocker medications affect FFF, but not motion perception. As suggested by Horton and Trobe (1999), motion perception deficits might only be found at much higher, perhaps even toxic levels, of these medications.

Original languageEnglish (US)
Pages (from-to)290a
JournalJournal of vision
Volume3
Issue number9
DOIs
StatePublished - Dec 1 2003

Fingerprint

Motion Perception
Flicker Fusion
Outpatients
Trazodone
Poisons
Task Performance and Analysis
Control Groups
Therapeutics

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems

Cite this

Motion perception with 5-HT2 receptor-blocking medications. / Christman, Chentel; Setterberg, Stephen; Nawrot, Mark.

In: Journal of vision, Vol. 3, No. 9, 01.12.2003, p. 290a.

Research output: Contribution to journalArticle

Christman, Chentel ; Setterberg, Stephen ; Nawrot, Mark. / Motion perception with 5-HT2 receptor-blocking medications. In: Journal of vision. 2003 ; Vol. 3, No. 9. pp. 290a.
@article{6c12c114ad83409a98ef41bb2ea275be,
title = "Motion perception with 5-HT2 receptor-blocking medications",
abstract = "It has been suggested that medications blocking 5- HT2 receptors may produce a selective motion perception deficit called akinetopsia. Horton and Trobe (1999) reported two cases of transient akinetopsia resulting from high doses of serzone (nefazadone). However, it is difficult to distinguish akinetopsia from more common visual side effects including palinopsia, a prolonged image of an object after it has moved or the observer looks away, and polyopia, multiple images of a moving object, based solely on patient report. Moreover, it is known that another similar 5- HT2 blocker, trazodone, lowers flicker fusion frequency (Riedel et al, 1999) although its effect on motion perception has not been investigated. In the current study, flicker fusion frequency (FFF) and motion perception were assessed in outpatients taking prescribed therapeutic doses of serzone and trazodone. FFF was assessed with LED's using method of limits with ascending and descending trials. Motion perception was assessed with the Ternus display and with a random-dot cinematogram display. The Ternus display used a 2AFC (element/group movement) task as inter-frame-interval varied between 0 and 60 msec. The random-dot cinematogram task used a 4AFC (up/down/left/right) task as the proportion of motion signal varied between 6{\%} and 34{\%}. Similar to Riedel et al (1999), the medicated outpatient group had significantly lower FFF than the normal control group. However, on the motion perception tasks, performance within the outpatient group was highly variable, but overall, the outpatient and normal groups were not significantly different. It appears that typical therapeutic doses of these 5- HT2 blocker medications affect FFF, but not motion perception. As suggested by Horton and Trobe (1999), motion perception deficits might only be found at much higher, perhaps even toxic levels, of these medications.",
author = "Chentel Christman and Stephen Setterberg and Mark Nawrot",
year = "2003",
month = "12",
day = "1",
doi = "10.1167/3.9.290",
language = "English (US)",
volume = "3",
pages = "290a",
journal = "Journal of Vision",
issn = "1534-7362",
publisher = "Association for Research in Vision and Ophthalmology Inc.",
number = "9",

}

TY - JOUR

T1 - Motion perception with 5-HT2 receptor-blocking medications

AU - Christman, Chentel

AU - Setterberg, Stephen

AU - Nawrot, Mark

PY - 2003/12/1

Y1 - 2003/12/1

N2 - It has been suggested that medications blocking 5- HT2 receptors may produce a selective motion perception deficit called akinetopsia. Horton and Trobe (1999) reported two cases of transient akinetopsia resulting from high doses of serzone (nefazadone). However, it is difficult to distinguish akinetopsia from more common visual side effects including palinopsia, a prolonged image of an object after it has moved or the observer looks away, and polyopia, multiple images of a moving object, based solely on patient report. Moreover, it is known that another similar 5- HT2 blocker, trazodone, lowers flicker fusion frequency (Riedel et al, 1999) although its effect on motion perception has not been investigated. In the current study, flicker fusion frequency (FFF) and motion perception were assessed in outpatients taking prescribed therapeutic doses of serzone and trazodone. FFF was assessed with LED's using method of limits with ascending and descending trials. Motion perception was assessed with the Ternus display and with a random-dot cinematogram display. The Ternus display used a 2AFC (element/group movement) task as inter-frame-interval varied between 0 and 60 msec. The random-dot cinematogram task used a 4AFC (up/down/left/right) task as the proportion of motion signal varied between 6% and 34%. Similar to Riedel et al (1999), the medicated outpatient group had significantly lower FFF than the normal control group. However, on the motion perception tasks, performance within the outpatient group was highly variable, but overall, the outpatient and normal groups were not significantly different. It appears that typical therapeutic doses of these 5- HT2 blocker medications affect FFF, but not motion perception. As suggested by Horton and Trobe (1999), motion perception deficits might only be found at much higher, perhaps even toxic levels, of these medications.

AB - It has been suggested that medications blocking 5- HT2 receptors may produce a selective motion perception deficit called akinetopsia. Horton and Trobe (1999) reported two cases of transient akinetopsia resulting from high doses of serzone (nefazadone). However, it is difficult to distinguish akinetopsia from more common visual side effects including palinopsia, a prolonged image of an object after it has moved or the observer looks away, and polyopia, multiple images of a moving object, based solely on patient report. Moreover, it is known that another similar 5- HT2 blocker, trazodone, lowers flicker fusion frequency (Riedel et al, 1999) although its effect on motion perception has not been investigated. In the current study, flicker fusion frequency (FFF) and motion perception were assessed in outpatients taking prescribed therapeutic doses of serzone and trazodone. FFF was assessed with LED's using method of limits with ascending and descending trials. Motion perception was assessed with the Ternus display and with a random-dot cinematogram display. The Ternus display used a 2AFC (element/group movement) task as inter-frame-interval varied between 0 and 60 msec. The random-dot cinematogram task used a 4AFC (up/down/left/right) task as the proportion of motion signal varied between 6% and 34%. Similar to Riedel et al (1999), the medicated outpatient group had significantly lower FFF than the normal control group. However, on the motion perception tasks, performance within the outpatient group was highly variable, but overall, the outpatient and normal groups were not significantly different. It appears that typical therapeutic doses of these 5- HT2 blocker medications affect FFF, but not motion perception. As suggested by Horton and Trobe (1999), motion perception deficits might only be found at much higher, perhaps even toxic levels, of these medications.

UR - http://www.scopus.com/inward/record.url?scp=4243114220&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4243114220&partnerID=8YFLogxK

U2 - 10.1167/3.9.290

DO - 10.1167/3.9.290

M3 - Article

AN - SCOPUS:4243114220

VL - 3

SP - 290a

JO - Journal of Vision

JF - Journal of Vision

SN - 1534-7362

IS - 9

ER -